keyword
MENU ▼
Read by QxMD icon Read
search

Axitinib

keyword
https://www.readbyqxmd.com/read/29780111/life-threatening-hyperkalemia-associated-with-axitinib-treatment-in-patients-with-recurrent-renal-carcinoma-a-case-report
#1
Shigeo Godo, Yoshitaro Yoshida, Naoki Kawamorita, Koji Mitsuzuka, Yu Kawazoe, Motoo Fujita, Daisuke Kudo, Ryosuke Nomura, Hiroaki Shimokawa, Shigeki Kushimoto
Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was well-tolerated in clinical trials, the real-world safety and tolerability remain unverified. We herein report a patient with metastatic renal cell carcinoma who suddenly developed life-threatening hyperkalemia following the initiation of axitinib treatment. Although hyperkalemia has been reported with an incidence of <10%, acute severe hyperkalemia may be a considerably critical adverse event of axitinib therapy, especially in patients with risk factors for hyperkalemia...
May 18, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29773888/antitumor-effect-of-axitinib-combined-with-dopamine-and-pk-pd-modeling-in-the-treatment-of-human-breast-cancer-xenograft
#2
Yuan-Heng Ma, Si-Yuan Wang, Yu-Peng Ren, Jian Li, Ting-Jie Guo, Wei Lu, Tian-Yan Zhou
Rising evidence has shown the development of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors in the practices of cancer therapy. It is reported that the efficacy of axitinib (AX), a VEGFR inhibitor, is limited in the treatment of breast cancer as a single agent or in combination with other chemotherapeutic drugs due to the probability of rising population of cancer stem-like cells (CSCs) caused by AX. The present study evaluated the effect of dopamine (DA) improving AX's efficacy on MCF-7/ADR breast cancer in vitro and in vivo, and developed a pharmacokinetic-pharmacodynamic (PK-PD) model describing the in vivo experimental data and characterizing the interaction of effect between AX and DA...
May 17, 2018: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29769293/emerging-multitarget-tyrosine-kinase-inhibitors-in-the-treatment-of-neuroendocrine-neoplasms
#3
Federica Grillo, Tullio Florio, Francesco Ferraù, Elda Kara, Giuseppe Fanciulli, Antongiulio Faggiano, Annamaria A L Colao
In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multi-target tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by regulatory agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in depth review on the studies published on the following MTKIs in neuroendocrine tumours: axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed...
May 16, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29765173/hemodiafiltration-and-plasma-levels-of-axitinib-in-a-patient-with-metastatic-renal-clear-cell-carcinoma
#4
Jindrich Kopecky, Alena Ticha, Hana Janeckova, Melichar Bohuslav
BACKGROUND: The standard treatment for metastatic renal cancer is based on vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTor) inhibitors. Compared to other advanced tumors, the treatment of renal cancer is highly affected by impaired renal function; therefore, patients with severe renal insufficiency, including patients on hemodialysis, are generally excluded from clinical trials. CASE REPORT: In the present manuscript we present the case of a renal cancer patient who underwent bilateral nephrectomy and received two lines of treatment...
May 15, 2018: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/29746290/intestinal-pneumatosis-a-manifestation-of-rarely-reported-axitinib-associated-necrotizing-enterocolitis
#5
Komal Akhtar, Adam Zayac, Sheila Lemke
No abstract text is available yet for this article.
May 1, 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29721663/combined-vegf-pdgf-inhibition-using-axitinib-induces-%C3%AE-sma-expression-and-a-pro-fibrotic-phenotype-in-human-pericytes
#6
Jakob Siedlecki, Ben Asani, Christian Wertheimer, Anna Hillenmayer, Andreas Ohlmann, Claudia Priglinger, Siegfried Priglinger, Armin Wolf, Kirsten Eibl-Lindner
PURPOSE: Large trials on anti-VEGF/PDGF (vascular endothelial/platelet-derived growth factor) combination therapy have been established to improve management of neovascular activity in age-related macular degeneration. Targeting pericytes, PDGF is thought to induce vessel regression and reduce fibrovascular scarring. The fate of pericytes exposed to anti-VEGF/PDGF combination therapy is not clear. Therefore, this study was designed to study the influence of anti-VEGF/PDGF on pericyte phenotype and cellular behavior...
May 2, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29719575/bromide-assisted-chemoselective-heck-reaction-of-3-bromoindazoles-under-high-speed-ball-milling-conditions-synthesis-of-axitinib
#7
Jingbo Yu, Zikun Hong, Xinjie Yang, Yu Jiang, Zhijiang Jiang, Weike Su
A mechanically-activated chemoselective Heck coupling for the synthesis of 3-vinylindazoles has been developed with the aid of catalytic amounts of TBAB and NaBr as both dehalogenation restrainer and grinding auxiliary. After tuning of the chemical conditions and mechanical parameters, a series of non-activated 3-bromoindazoles and a broad scope of olefins worked well to give the corresponding coupling products in good to excellent yields. A further application of this protocol was performed in a two-step mechanochemical Heck/Migita cross coupling, which provided a highly efficient route for the synthesis of axitinib...
2018: Beilstein Journal of Organic Chemistry
https://www.readbyqxmd.com/read/29719414/cost-effectiveness-comparison-of-cabozantinib-with-everolimus-axitinib-and-nivolumab-in-the-treatment-of-advanced-renal-cell-carcinoma-following-the-failure-of-prior-therapy-in-england
#8
Jie Meng, Johanna Lister, Anne-Lise Vataire, Roman Casciano, Jerome Dinet
Purpose: The aim of this study was to compare the cost-effectiveness of cabozantinib with the standard of care in England in adult patients with advanced renal cell carcinoma (aRCC), following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy. Methods: We developed a partitioned-survival model with three health states to assess the cost-effectiveness of cabozantinib and its comparators. The model time horizon was 30 years. Efficacy and safety data were derived from pivotal clinical trials (METEOR: NCT01865747, CheckMate025: NCT01668784, and AXIS: NCT00678392)...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29716831/in-vivo-mr-in-the-drug-pipeline
#9
Jeffrey L Evelhoch
The application of in vivo magnetic resonance (MR) in drug development has several requirements that differ significantly from most applications primarily because the biopharmaceutical industry must develop new safe and effective drugs more quickly and at lower cost in a highly regulated environment. In vivo MR is recognized as a useful method to provide biomarkers for target engagement, treatment response, safety and mechanism of action that can be translated between animal and clinical studies. Thus, it has the potential to help identify drugs that are more likely to be safe and effective earlier in the process of drug development, which may help reduce the time and money required to get new drugs to patients with an unmet medical need...
April 25, 2018: Journal of Magnetic Resonance
https://www.readbyqxmd.com/read/29695637/a-high-content-screening-of-anti-cancer-compounds-suggests-the-multiple-tyrosine-kinase-inhibitor-ponatinib-for-repurposing-in-neuroblastoma-therapy
#10
Viktoryia Sidarovich, Marilena De Mariano, Sanja Aveic, Michael Pancher, Valentina Adami, Pamela Gatto, Silvia Pizzini, Luigi Pasini, Michela Croce, Federica Parodi, Flora Cimmino, Marianna Avitabile, Laura Emionite, Michele Cilli, Silvano Ferrini, Aldo Pagano, Mario Capasso, Alessandro Quattrone, Gian Paolo Tonini, Luca Longo
Novel druggable targets have been discovered in neuroblastoma (NB), paving the way for more effective treatments. However, children with high-risk NB still show high mortality rates prompting for a search of novel therapeutic options. Here, we aimed at repurposing FDA-approved drugs for NB treatment by performing a high-content screening of a 349 anti-cancer compounds library. In the primary screening we employed three NB cell lines, grown as 3D multicellular spheroids, which were treated with 10 μM of the library compounds for 72 hours...
April 25, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29692506/efficacy-and-safety-of-third-and-fourth-line-targeted-therapy-in-japanese-patients-with-metastatic-renal-cell-carcinoma-a-retrospective-analysis
#11
Negishi Takahito, Nagase Kei, Iwai Hidenori, Furubayashi Nobuki, Taguchi Kenichi, Nakamura Motonobu
Introduction: There is limited data on the efficacy of sequential targeted therapy for metastatic renal cell carcinoma (mRCC) beyond the second line, especially for Asian patients. We evaluated the efficacy and side effects of targeted therapy beyond the second line. Materials and Methods: We retrospectively reviewed 69 patients who were administered targeted therapy for mRCC at our institution between 2008 and 2016. Sunitinib, pazopanib, sorafenib, axitinib, everolimus, and temsirolimus were available in Japan in 2016, and treatment had been conducted with those six agents...
April 2018: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/29684948/-successful-treatment-of-peritoneal-dissemination-recurrence-with-axitinib-in-papillary-renal-cell-carcinoma-a-case-report
#12
Junichi Mori, Yuki Nakayama, Tsuyoshi Hiragino, Hideyasu Matsuyama
We report a case of successful treatment of recurrence of peritoneal dissemination with axitinib. A 55-year-old man presented at our hospital with the chief complaint of remarkable abdominal fullness 18 months after right radical nephrectomy, which had been performed at another hospital for the treatment of renal cell carcinoma. The pathological diagnosis was papillary renal cell carcinoma type 1, pT3aN0M0. A large amount of ascites was detected by computed tomography, and recurrence of peritoneal dissemination was diagnosed (ascites cytology : class V)...
February 2018: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29682213/pharmacogenetics-based-area-under-curve-model-can-predict-efficacy-and-adverse-events-from-axitinib-in-individual-patients-with-advanced-renal-cell-carcinoma
#13
Yoshiaki Yamamoto, Ryouichi Tsunedomi, Yusuke Fujita, Toru Otori, Mitsuyoshi Ohba, Yoshihisa Kawai, Hiroshi Hirata, Hiroaki Matsumoto, Jun Haginaka, Shigeo Suzuki, Rajvir Dahiya, Yoshihiko Hamamoto, Kenji Matsuyama, Shoichi Hazama, Hiroaki Nagano, Hideyasu Matsuyama
We investigated the relationship between axitinib pharmacogenetics and clinical efficacy/adverse events in advanced renal cell carcinoma (RCC) and established a model to predict clinical efficacy and adverse events using pharmacokinetic and gene polymorphisms related to drug metabolism and efflux in a phase II trial. We prospectively evaluated the area under the plasma concentration-time curve (AUC) of axitinib, objective response rate, and adverse events in 44 consecutive advanced RCC patients treated with axitinib...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29658816/a-mixed-treatment-comparison-of-toxicity-of-gemcitabine-combined-with-different-targeted-drugs-in-the-treatment-of-advanced-or-metastatic-pancreatic-cancer
#14
Penpa Dorjee, Zi-Wen Long
The mixed treatment comparison study was performed in order to compare the toxicities of Gemcitabine and different targeted drug combinations in the treatment of advanced/metastatic pancreatic cancer (PC). Searches were performed from the inception of PubMed and Cochrane Library databases to February 2017. This study included randomized controlled trials (RCTs) of Gemcitabine and different targeted drug combinations in the treatment of advanced/metastatic PC. Odds ratio (OR) values were calculated by direct and indirect comparisons, and the surface under the cumulative ranking curves (SUCRA) were drawn...
April 16, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29650821/-continuation-of-axitinib-for-advanced-renal-cell-carcinoma-by-the-application-of-homecare-urology-a-case-report-and-literature-review
#15
Satoshi Yazawa, Yuji Kato, Jin Nakahara, Toshio Miyata, Mototsugu Oya
A 56-year-old man with advanced RCC and a past medical history of type 2 diabetes underwent a radical left nephrectomy following a histological diagnosis of papillary RCC, G2, INF b, pT3, V1 in 1999. In 2008, sorafenib was started to treat multiple pulmonary metastases of RCC. In 2011, sorafenib was switched to sunitinib when radiologic progression was observed. In 2014, sunitinib was switched to axitinib when further radiologic progression was observed. In 2015, the patient was referred to Yazawa clinic for homecare urology when hospital visits became difficult due to cancer pain and bilateral lower-extremity muscle weakness...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29599413/combinatorial-effects-of-vegfr-kinase-inhibitor-axitinib-and-oncolytic-virotherapy-in-mouse-and-human-glioblastoma-stem-like-cell-models
#16
Dipongkor Saha, Hiroaki Wakimoto, Cole W Peters, Slawomir J Antoszczyk, Samuel D Rabkin, Robert L Martuza
PURPOSE: Glioblastoma (GBM), a fatal brain cancer, contains a subpopulation of GBM stem-like cells (GSCs) that contribute to resistance to current therapy. Angiogenesis also plays a key role in GBM progression. Therefore, we developed a strategy to target the complex GBM microenvironment, including GSCs and tumor vasculature. EXPERIMENTAL DESIGN: We evaluated the cytotoxic effects of VEFGR tyrosine kinase inhibitor (TKI) axitinib in vitro and then tested anti-tumor efficacy of axitinib in combination with oncolytic herpes simplex virus (oHSV) expressing anti-angiogenic cytokine murine IL12 (G47Δ-mIL12) in two orthotopic GSC-derived GBM models: patientderived recurrent MGG123 GSCs, forming vascular xenografts in immune-deficient mice, and mouse 005 GSCs, forming syngeneic tumors in immune-competent mice...
March 29, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29587324/-immunotherapy-for-renal-cell-carcinoma-current-status
#17
Marc-Oliver Grimm, Susan Foller
Systemic treatment of metastatic renal cell carcinoma (mRCC) has substantially changed during the last 2 years due to approval of the immune-checkpoint inhibitor Nivolumab (Opdivo® ) and new multikinase inhibitors (Cabozantinib, Lenvatinib, Tivozanib). The german kidney tumor guideline strongly recommends Nivolumab and Cabozantinib as 2nd line treatments after prior VEGF targeted therapy. CheckMate 025, the prospective randomized trial which led to approval of Nivolumab demonstrated improved overall survival (26 month vs...
April 2018: Aktuelle Urologie
https://www.readbyqxmd.com/read/29578848/the-additional-costs-per-month-of-progression-free-survival-and-overall-survival-an-economic-model-comparing-everolimus-with-cabozantinib-nivolumab-and-axitinib-for-second-line-treatment-of-metastatic-renal-cell-carcinoma
#18
Elyse Swallow, Andrew Messali, Sameer Ghate, Evangeline McDonald, Emilie Duchesneau, Jose Ricardo Perez
BACKGROUND: When considering optimal second-line treatments for metastatic renal cell carcinoma (mRCC), clinicians and payers seek to understand the relative clinical benefits and costs of treatment. OBJECTIVE: To use an economic model to compare the additional cost per month of overall survival (OS) and of progression-free survival (PFS) for cabozantinib, nivolumab, and axitinib with everolimus for the second-line treatment of mRCC from a third-party U.S. payer perspective...
April 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29575989/financial-impact-of-oral-chemotherapy-wastage-on-society-and-the-patient
#19
Varun Monga, Chenise Meyer, Brandon Vakiner, Gerald Clamon
Background Targeted oral agents are now increasingly being utilized in cancer treatment, but are expensive. Changing the dose of these medications due to toxicity or discontinuation secondary to disease progression or death causes waste from unused medication. Limiting waste is an important goal, as waste has a substantial financial impact on patients and insurance companies. Methods Patients started on oral targeted agents' sunitinib, everolimus, axitinib, or vemurafenib between January 2012 and February 2015 who obtained their medications at Holden Comprehensive Cancer Center specialty pharmacy were included in the analysis...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29570686/design-synthesis-and-biological-evaluation-of-axitinib-derivatives
#20
Na Wei, Jianqing Liang, Shengming Peng, Qiang Sun, Qiuyun Dai, Mingxin Dong
Axitinib is an approved kinase inhibitor for the therapy of advanced metastatic renal cell carcinoma (RCC). It prevents angiogenesis, cellular adhesion, and induces apoptosis of cancer cells. Here, nine axitinib derivatives were designed by replacing the C=C moiety with the N=N group, and the substituted benzene or pyrrole analogs were considered to replace the pyridine ring. Biological activity results showed that most of nascent derivatives exhibited favorable VEGFR-2 kinase inhibitory activities, and TM6 , 7 , 9 , and 11 behaved more potent anti-proliferative activities than axitinib...
March 23, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
keyword
keyword
21146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"